Leigh Vosseller: A lot of good questions there. Probably, first, I should start off just saying what is our primary goal for pharmacy channel. And number one, it’s increasing access for patients and reducing out-of-pocket cost. Number two is when we look at the economics, it should be at least as good as or better than what we see in DME today. And what pharmacy provides for us is a unique opportunity when we think about the business model, and it will allow us to shape it in a way that could look different from DME, but also it could look just like DME. And so in some cases, I think we’re going to see variability payer-by-payer and PBM by PBM in terms of how that shapes up. And so when we think about that in the longer term, I would say we are being very selective about which contracts we take, which ones are going to be good for the business, just considering all options with what it comes down to it.
And so we don’t think this will be materially disruptive to our top line. It’s going to be a multiyear build. And remember, it’s focused on Mobi only. So it’s not touching the whole business altogether. And so we’re really excited for it. We think it will be really good for the business and stay tuned. We look forward to giving updates as we have more conversations with payers.
Michael Polark: Helpful. Thank you.
Operator: Thank you. One moment for our next question. And our next question comes from the line of Matt Miksic from Barclays. Your question, please.
Matt Miksic: Yes. Thanks so much for taking the questions and congrats on a really terrific quarter here. So first, I know someone had asked earlier about guidance, I just wanted to make sure we understand how you’re thinking about going about it. And then I have one follow-up to the – on guidance, just sticking to the plans, renewal only, not yet sort of making any bold predictions about Mobi. Is that begin in Q2, do you think to begin in Q3? When do you think you’ll have enough to know on that front color there, I guess, given that things seem to be picking up pretty quickly? And then I had one follow-up.
Leigh Vosseller: Sure. So it is the same philosophy for guidance now as when we started the year. The only difference is that the outperformance we had in the first quarter, we’ve now added into the guidance for the remainder of the year. So still heavily based on the renewal opportunity that we have in front of us, the increasing supply sales. And from a new pumper perspective, we want to see more trends. And so thinking about Mobi and watching it through its launch, it’s been – it’s a staged launch. And so we started with direct customers only, just shifted to the distribution channel at the end of the first quarter. G7 integration won’t come until late in the second quarter. And so that’s causing impact on customer behavior on when they’re making their pump purchases.
So I think we probably need at least third quarter to kind of see how things settle in. The exciting part about it all is through all of this even though it’s limited data, the data points tell us that things are in line with our market research. And so we think there’s great opportunity here, but we’re going to be reluctant to factor anything into the guidance until we can feel more confident about how it settles out.
Matt Miksic: That’s helpful. And then just the other question is a more sort of general one. I think someone else again had asked earlier in the call about like where you’re expanding the market, where you’re maybe – were you seeing more traction, but anything that you can – if you’re seeing a pattern of or these folks really seem to gravitate towards one of the two platforms or the other. And then it also came up on the call is often does this idea of tubeless. And I know that you have a somewhat different philosophy about the product portfolio that you’re building out and how you think about defining your pump offerings and around tubeless or wearability, if you can maybe kind of more broadly expand on your philosophy there as you kind of get through tubeless, Mobi and into Sigi? Thanks.
John Sheridan: Yes. Matt, I think when you look at the data that we’ve collected so far, of course, we’re paying very close attention to it. We know the age. We know how long people have had diabetes. We know all of the characteristics of the people who are using them will be at this point in time. But as Leigh had said, it’s really been the stage launch, and it hasn’t been out there yet, long enough, I think, for us to draw any conclusions. We’re very excited about how many people are coming to use Mobi from MDI, which we think is a real positive. But it’s a bit too early for us to say, here are some of the characteristics of the people because I don’t think it would be reflective. And I’m afraid that we – after we get more people on it in a quarter or so, it might change.
So just stay tuned, and we’ll definitely keep you informed about how it looks, and we’ll just go from there. And then when it comes to our portfolio approach, we think that it’s important to provide people choice. Choice and how they wear, how they control and how they interact with the product. And our research suggests that there are distinct groups of people out there with type 1 and type 2 that want a pump that has a controller on it that has the interface on the system. That’s small and gives you another device, Mobi, that gives you the flexibility of various wear options, mobile control and great outcome performance. And then finally, a complete tubeless system that’s a very wearable and rechargeable system. So we – our research suggests that those are all meaningful market segments and that – and we intend to continue to pursue that.
Each of them are different. And I think that – we think that’s the right strategy. And I think that it resonates with a lot of the people we are talking about as we do this research.
Matt Miksic: Thanks so much, John.
John Sheridan: Yes. Take care, Matt.
Operator: Thank you. This does conclude the question-and-answer session as well as today’s program. Thank you for your participation. You may now disconnect. Good day.
